FDA approves Eli Lilly’s migraine drug

Organisation: Position: Deadline Date: Location:

The US Food and Drug Administration (FDA) has announced that it had approved Eli Lilly and Co’s migraine drug, Reyvow. Reuters Health report that the drug has been approved to treat acute migraine with or without aura, a sensory phenomenon or visual disturbance, in adults.

Lilly acquired Reyvow, formerly called lasmiditan, in a deal worth about $960m when it bought CoLucid Pharmaceuticals Inc in early 2017. Lasmiditan was first developed at Lilly, but later licensed out to CoLucid in 2005. Lilly said the price of Reyvow will be determined closer to the time of commercial availability.

The report says according to the Migraine Research Foundation, roughly 39m Americans suffer from migraine headaches. The FDA advises patients not to drive or operate machinery for at least eight hours after taking Reyvow, as the drug causes dizziness and sedation.

Reuters Health report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.